
UbiVac: A Portland-based biotech firm specializing in the development of therapeutic cancer vaccines.
Founded in 2005 in Portland, Oregon, UbiVac is a clinical-stage biotechnology company focused on developing therapeutic vaccines to combat cancer. Originating as a spinout from the Robert W. Franz Cancer Research Center at the Earle A. Chiles Research Institute within Providence Portland Medical Center, UbiVac aims to harness the body's immune system to target and eliminate cancer cells. The company's core mission is to innovate and advance immunotherapy treatments, with a vision to transform cancer care through cutting-edge vaccine technologies.
UbiVac has attracted notable affiliations, including leading oncologists and researchers from prestigious institutions. The company has secured investments from prominent venture capital firms and has achieved significant milestones in clinical trials, demonstrating promising results in cancer immunotherapy. UbiVac's impact extends beyond research, contributing to the broader scientific community through publications and collaborations, positioning itself as a key player in the fight against cancer.

Cancervax
cancervax.com

EpiVax Oncology
epivaxtx.com

Uvax Bio
uvaxbio.com

Adventris Pharmaceuticals

Agilvax

MimiVax
mimivax.com

Pathovax
pathovax.com

Irazu Oncology
irazuoncology.com

CellVax Therapeutics
cellvx.com

Sequoia Sciences

Solaris Vaccines
solarisvax.com

Vivacitas Oncology
vivaoncology.com

Madison Vaccines

InvVax
inv-vax.com

Immunophotonics
Companies similar to Ubivac include Cancervax, EpiVax Oncology, Uvax Bio and Adventris Pharmaceuticals.
Ubivac was founded in 2005.
Ubivac's headquarters is located in Portland, OR, US.
Ubivac's most recent funding round was for $250k (USD) in April 2022.
As of Apr 14, 2022, Ubivac has raised a total of $2.2M (USD).
Ubivac has 11 employees as of Feb 5, 2024.